微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 26.04% | 0.07% | -8.05% | 124/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 28.32% | 3.33% | 9.25% | 123/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 25.93% | -4.82% | -0.28% | 128/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 26% | -8.12% | -0.11% | 127/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 26.02% | -14% | -5.05% | 127/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 27.41% | 0.48% | 0.63% | 125/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 27.24% | -7.18% | -3.73% | 126/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 28.29% | -7.19% | -6.5% | 125/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 30.26% | 2.44% | 10.94% | 119/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.28% | -3.42% | -7.04% | 128/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 29.34% | -6.11% | -3.75% | 117/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 30.49% | -2.91% | 3.2% | 118/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 29.54% | -5.43% | 4.59% | 117/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 28.24% | -17.45% | -9.63% | 132/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.25% | -17.07% | -0.47% | 111/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 31.4% | -20.58% | 0.52% | 121/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 31.24% | -22.74% | -8.7% | 105/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 34.21% | -0.62% | -9.22% | 120/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 37.69% | 9.3% | -4.67% | 96/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 39.53% | 12.16% | -2.22% | 99/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 40.43% | 10.6% | 17.43% | 83/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 34.43% | 10.68% | -0.15% | 112/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 34.48% | 10.32% | -2.18% | 90/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 35.25% | 10.45% | -3.58% | 93/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.56% | 2% | 17.51% | 82/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 31.11% | -10.96% | -0.48% | 115/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 31.26% | 2% | -2.06% | 87/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 31.91% | -14.12% | -8.65% | 88/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 34.94% | -13.15% | -5.99% | 91/159 | 52.58% | 贝达药业 | 95.54% | 行业排名> |
| 2017-06-30 | 37.16% | 2% | -7.62% | 73/159 | 48.02% | 贝达药业 | 95.74% | 行业排名> |
| 2016-12-31 | 40.22% | 25.36% | 25.36% | 69/159 | 48.44% | 退市金泰 | 96.19% | 行业排名> |
| 2015-12-31 | 32.09% | 25.5% | 25.5% | 78/159 | 46.24% | 贝达药业 | 95.81% | 行业排名> |